Emerging psychosis in young people – Part 2
Key issues for acute management

BACKGROUND
To optimise the management of emerging psychotic disorders in young people, close collaboration between the general practitioner and youth friendly specialist mental health services is favourable. Ideally, a multidisciplinary team including individual case management with expertise in early intervention should treat these patients for the initial 2–5 years. However, only a few areas across Australia currently provide this type of specialised service. Most GPs will at some point be faced with the reality of personally managing young patients with emerging psychotic disorders on their own, sometimes with very limited support.

OBJECTIVE
This article summarises key issues for the optimal management of emerging psychotic disorders, with a particular focus on the role of the GP.

DISCUSSION
Once an emerging psychotic disorder is confirmed, the engagement of the young person into therapy is the primary target. Ideally therapy integrates not only the patient, but also their family, carers and friends. General practitioners need to inform patients about the nature of the emerging psychotic illness, manage related comorbidities such as substance abuse, and initiate antipsychotic medication to avoid any unnecessary delay in resolution of symptoms. It is important to monitor the patient on a regular basis even after symptom recovery as up to 80% of cases that cease medication will relapse within 5 years.

General practitioners are often the first point of contact for a distressed family or young person experiencing symptoms of an emerging psychotic illness. Once a psychotic illness has been confirmed, it is essential to formulate and implement an appropriate management plan. Ideally early referral to a specialised early psychosis service (eg, the Early Psychosis Prevention & Intervention Centre (EPPIC) of ORYGEN Youth Health) should be arranged so that appropriate treatment can be initiated. Unfortunately in many areas such services do not exist or alternatives such as adult or child mental health services or private services are unable to respond in a timely fashion. Under these circumstances, GPs may have to initiate management of the young patient themselves, as the evidence base consistently supports early intervention with the aim of reducing the duration of untreated psychosis and minimising social and cognitive incapacity in order to improve overall outcome.

Management of the first psychotic episode
An integrated bio-psycho-social treatment approach
Optimal treatment integrates biological, psychological and social interventions at the earliest possible opportunity. The ideal model for the optimal therapy of a first psychotic episode involves a multidisciplinary approach including the GP, a psychiatrist, psychologist, mental health nurse, occupational therapist, social worker, and most importantly, long term case management with vocational recovery goals. Any of the above clinicians can take on the role of the case manager and it may depend on the individual needs of the patient and the available resources as to who is best suited. The case manager will maintain contact – even after full recovery – to monitor, along with the GP, maintenance treatment and to look out for the early warning signs of relapse.

At the EPPIC program of ORYGEN Youth Health, each patient is allocated a case manager to: coordinate...
care, promote development of the individual, minimise psychosocial stressors, and ensure ongoing treatment adherence and engagement with services. This approach is particularly important in the early phase of illness until the patient is able to take on a large proportion of responsibility for the management of his/her illness. Unfortunately such services are not yet available in most areas of Australia. Adult mental health services may not be appropriately resourced or motivated to follow up early psychosis cases after the initial recovery, and frequently discharge patients prematurely during early recovery with limited follow up. General practitioners are then often responsible for the ongoing care of these patients.

**Keeping patients engaged – the therapeutic alliance**

The engagement of the patient in a long term therapeutic alliance where treatment can be tailored to the patient’s individual needs is a prerequisite to achieve optimal outcome. A common perception is that the mainstay of treatment in first episode psychosis is solely antipsychotic medication. This may be true to some extent, as recent evidence suggests that newer antipsychotic medications protect the brain from damage in patients undergoing a first psychotic episode and can be beneficial in enhancing cognitive functioning. However, treatment adherence is very poor – in the region of 60% for patients with psychosis and relapses are frequent. About 80% of patients who cease antipsychotic medication relapse within 5 years. The likelihood of remission drops with every relapse. Therefore, the engagement of the patient into a long term therapeutic alliance for several years is recommended (see Case history Mary).

**Antipsychotic medication – first impressions**

The patient’s initial experience with using antipsychotic medication is a key factor in determining their long term attitude toward medication. The newer atypical antipsychotic medications (eg. olanzapine, quetiapine, risperidone or aripiprazole) provide fewer troublesome experiences such as extrapyramidal side effects (dystonia, tremor), restlessness, or sexual dysfunction compared to conventional antipsychotic medications. The risk of long term side effects such as tardive dyskinesia is also lower. They may also have greater efficacy in the treatment of negative symptoms and better long term outcome, and their subjective tolerability is better and are therefore less likely to be discontinued prematurely.

**Which is the right drug for my patient?**

Atypical antipsychotics have demonstrated efficacy in reducing positive (eg. hallucinations and delusions) and negative (eg. social withdrawal) symptoms associated with psychotic illnesses such as schizophrenia or bipolar disorder. Overall, most atypical antipsychotics have similar efficacy and the choice of agent is more dependant on side effect profile and the patient’s preference than on efficacy. In cases where sleep disturbance is a major problem, the prescription of a sedating drug such as quetiapine or olanzapine as a once daily dose at night may be beneficial compared to other less sedating atypical antipsychotic medications. Alternatively, the prescription of an antipsychotic medication with no or minimal weight gain may be preferable in an already overweight patient or for those very conscious of their body image. In young sexually active males, one might avoid medications with high rates of prolactin elevation (eg. amisulpride, risperidone) as a first line treatment to prevent premature discontinuation. To promote treatment adherence, it is important that the prescribing doctor involves the patient in the decision making process – which atypical antipsychotic is best suited for the needs of the individual patient together with information about the most common side effects, which will be transient in most cases. The doctor needs to monitor emerging side effects closely and adapt the treatment accordingly to further promote adherence.

**Start low and go slow (finding the optimal dose)**

In general, the dose of antipsychotic medication in drug naïve first episode psychosis patients is usually about half the recommended dose for chronic schizophrenia (Table 1). However, finding the individual minimal effective dose – this should be the lowest dose of medication providing symptom control – is not an easy task (in particular with the newer antipsychotic agents) and there is a risk of unnecessary dose escalation. To ensure appropriate dose titration, frequent assessment of clinical response and side effects (at least weekly) after treatment initiation is necessary. This will also help to establish a therapeutic alliance.

Antipsychotic medication usually takes 1–2 weeks to show a symptomatic response. If first episode psychosis patients do not show a marked improvement within the initial 2 weeks of treatment, the atypical antipsychotic medication dose should be increased at fortnightly intervals until clear signs of response occur, but only within the limits of side effect emergence (eg. sedation and extrapyramidal...
For many patients this phase of illness is difficult due to ongoing symptoms. Short term use of benzodiazepines (eg. diazepam 2 mg 3 times per day and diazepam as required) to control tension, agitation or sleep disturbance can help and is recommended.

If the first line treatment does not show satisfactory symptomatic response within 6–8 weeks at an appropriate dose, we recommend switching to another atypical antipsychotic. Again, the choice of second line treatment should be discussed with the patient and the individual preferences of the patient should be taken into account. Cross tapering old and new treatment is the preferred method for switching and involves tapering off the previous antipsychotic agent and any adjunctive treatment (sedatives, anticholinergic medication), while gradually titrating the new atypical antipsychotic agent to the established therapeutic dose. The second line treatment will usually require higher doses than the recommended dose for drug naïve first episode psychosis patients (Table 1).

Never change a winning horse

The antipsychotic drug resulting in a symptomatic and functional recovery should be continued for at least a year (or longer) in order to minimise the risk of relapse and should not be changed gratuitously. However, despite encouraging high initial response rates to antipsychotic medication in first episode psychosis,29–31 up to 80% of patients will relapse due to high rates of discontinuation,13 even after 1 year of persistent remission of symptoms.32 The lifestyle change being expected of the young person with an emerging psychotic disorder represents a major challenge. Similar adjustment difficulties are seen in other potentially chronic illnesses such as juvenile onset diabetes, arthritis and asthma. The key predictors of medication adherence are the relationship with the prescribing clinician, previous experiences with hospital admissions, and insight into having a mental illness and the need for treatment.17 In most service areas across Australia, GPs will manage fully recovered first episode psychosis patients. They can make a big difference by engaging these patients in a long term therapeutic alliance, preventing traumatic admissions, and providing them with flexible approaches to manage their pharmacological treatment in a low stigma environment. To keep patients engaged, it may be necessary to negotiate a compromise, and intermittent antipsychotic medication may be preferable to ceasing the medication altogether.33,34

### Treating comorbidity

Comorbidity is very common in emerging psychotic disorders and needs to be managed carefully. Depression and anxiety occur in up to 50% of patients with a first episode psychosis35,36 and requires an integrated treatment approach. In most cases, depressive symptoms will resolve once the psychosis has been treated effectively.37 If depressive symptoms persist or are the dominant feature of the first psychotic episode, the use of selective serotonin reuptake inhibitors (SSRIs) to treat comorbid depression and anxiety is recommended, however the evidence is weak.35 More recent concerns regarding the use of SSRIs (except fluoxetine) potentially increasing suicide risk in children and adolescents38 has led to caution in prescribing for this age group. The combination of antipsychotic medication with mood stabilisers (eg. lithium and sodium valproate) to treat mood swings may be indicated, in particular in cases where the mood component is dominant or with a family history of treatment response to lithium. It may be that the mood stabiliser will be the primary long term treatment in some cases39 (see Case history Natalie). However, in such complex cases of emerging psychotic disorders, it is advisable to establish a treatment plan in liaison with a specialist service.

The link between drug use and psychosis is now well established38 and substance use disorder should be addressed either by the treating clinician or by specialist services. Use of illicit drugs can make teasing out complex symptomatology and assessing treatment response difficult for clinicians.

Personality factors can also complicate the overall picture, interacting with primary mental illness pathology and affecting clinical management. However, focusing on psychosis as a medical condition may facilitate treatment of these often difficult to engage patients. The GP is well placed to slowly engage such complex patients and initiate treatment and facilitate referral to a specialist mental health service once trust has been established.

### Identifying and managing risk

Risk assessment and management in early psychosis represents a critical component of the care plan. In particular, risk of suicide and violence are vital to quantify and manage. Around 10–15% of psychotic patients will eventually commit suicide40 and the risk is greatest in the first few years of illness.41,42

Although no individual intervention has

<table>
<thead>
<tr>
<th>Suggested lowest effective dose to treat</th>
<th>Neuroleptic naive FEP patients</th>
<th>Previously neuroleptic treated patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risperidone</td>
<td>2 mg/day</td>
<td>2–6 mg/day</td>
</tr>
<tr>
<td>Olanzapine</td>
<td>7.5 mg/day</td>
<td>15–30 mg/day</td>
</tr>
<tr>
<td>Quetiapine</td>
<td>200–300 mg/day</td>
<td>300–800 mg/day</td>
</tr>
<tr>
<td>Amisulpride</td>
<td>200–300 mg/day</td>
<td>&gt;400 mg/day</td>
</tr>
<tr>
<td>Aripiprazole</td>
<td>5–10 mg/day</td>
<td>10–30 mg/day</td>
</tr>
</tbody>
</table>

# Maintenance doses may vary on an individual basis
* Optimal dose has yet to be established for drug naïve first episode psychosis
† Lower doses to treat negative symptoms only (eg. 100 mg)
Making your patient an expert

Making your patient an expert

Psychosocial and psychological interventions including cognitive behavioural therapy (CBT) may reduce suicide risk. Such interventions aim to reduce stress, provide intensive support and decrease critical expressed emotion. Pharmacological management may involve the early use of clozapine in treatment resistant or highly suicidal patients with schizophrenia, lithium maintenance therapy in patients with affective psychosis, or consideration of electroconvulsive therapy (ECT) or the use of antidepressant medication to treat comorbid depression.

Predictors of serious violence tend to be similar to those for violence in the general population and include male gender, unemployment and substance abuse. Individuals diagnosed with psychotic illness can be at higher risk of harming others. Evidence regarding the relationship between specific symptoms and violence is not straightforward. Although it is important to recognise and address possible risk factors for violence in those with emerging psychosis, it is also important not to reinforce the stereotype of the ‘violent schizophrenic’ and perpetuate stigmatisation within mental illness.

Making your patient an expert

Mental illness awareness in patients and mental health literacy among patients and relatives of those with a first episode psychosis is poor. Providing knowledge about mental illness and treatment for patients and their families constitutes an important part of the management plan. Psychoeducation should be initiated at an early stage, focusing on illness explanation, treatment options and prognosis. This involves the patient, their family, carers and others such as teachers or friends. It is important to convey a message of hope and to promote therapeutic optimism for the patient and their family.

Conclusion

The role of the GP in the management of emerging major mental illnesses is important and generally adopts a shared care model with specialist mental health services. From initial recognition of the psychotic illness through to continuing care and relapse prevention, the GP should be involved in supporting the patient and their family. Regular communication between the mental health service and the GP is desirable in order to avoid confusion and minimise the chance of treatment failure. However, in many areas across Australia, GPs will be faced with the reality that they have to manage patients with emerging psychotic disorders with very limited support. In these instances it may be possible to obtain consultation from a specialist

Conflict of interest: none declared.

References


